Sol-Gel Technologies

Company Overview

Snapshot

Founded in October 1997 by Alon Seri-Levy, Sol-Gel Technologies operates with 11–50 employees. The company has raised a total of $146 million across seven funding rounds. In February 2018, Sol-Gel Technologies completed an Initial Public Offering on NASDAQ with a valuation of $225 million.

Business overview

Sol-Gel Technologies is a clinical-stage dermatology company specializing in the identification, development, and commercialization of branded and generic topical drug products for skin diseases. The company leverages its proprietary silica-based microencapsulation technology platform to develop its product pipeline, which includes late-stage branded candidates and several generic product candidates across multiple indications. Sol-Gel has successfully developed topical drugs like Twyneo and Epsolay for acne and inflammatory rosacea lesions, which are marketed in the US by Galderma. The company is also developing topical patidegib for Gorlin syndrome and topical erlotinib for pachyonychia congenita and other rare skin conditions, serving the pharmaceuticals and life sciences markets.

Strategic signal

In November 2023, Sol-Gel Technologies screened its first patient for the SGT-610 Phase 3 Study and hosted a virtual KOL event on Gorlin Syndrome, highlighting the upcoming Phase 3 trial for SGT-610. This indicates a significant advancement in its clinical pipeline, signaling potential for new product approvals and market expansion in the dermatology sector, particularly for rare skin indications.

Company Intelligence Q&A

What was a significant recent clinical development for Sol-Gel Technologies?

In November 2023, Sol-Gel Technologies screened its first patient for the SGT-610 Phase 3 Study, marking a key milestone in the development of its pipeline for Gorlin syndrome.

When did Sol-Gel Technologies report its third-quarter financial results in 2023?

Sol-Gel Technologies reported its third-quarter 2023 financial results and provided a corporate update in November 2023.

What was a notable commercial agreement for Sol-Gel Technologies in 2023?

In June 2023, Sol-Gel Technologies and Searchlight Pharma announced licensing agreements to commercialize TWYNEO and EPSOLAY in Canada.

What was a key strategic acquisition for Sol-Gel Technologies in early 2023?

In January 2023, Sol-Gel Technologies acquired Patidegib, a Phase 3, FDA-Breakthrough-Designated orphan product candidate, to pursue a potential market of over $300 million.

When did Sol-Gel Technologies announce its U.S. commercial partner Galderma would promote TWYNEO?

In March 2022, Sol-Gel Technologies announced that its U.S. Commercial Partner Galderma would promote TWYNEO at the American Academy of Dermatology Annual Meeting.